

LJMU Research Online

Wallach, J, Kavanagh, PV, Mclaughlin, G, Morris, N, Power, JD, Elliott, SP, Mercier, MS, Lodge, D, Morris, H, Dempster, NM and Brandt, SD

Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers

http://researchonline.ljmu.ac.uk/id/eprint/3408/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Wallach, J, Kavanagh, PV, Mclaughlin, G, Morris, N, Power, JD, Elliott, SP, Mercier, MS, Lodge, D, Morris, H, Dempster, NM and Brandt, SD (2015) Preparation and characterization of the 'research chemical' diphenidine, its pvrrolidine analogue. and their 2.2-diphenvlethvl isomers. Drug Testing and

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers

Jason Wallach, Pierce V. Kavanagh, Gavin McLaughlin, Noreen Morris, John D. Power, Simon P. Elliott, Marion S. Mercier, David Lodge, Hamilton Morris, Nicola M. Dempster, Simon D. Brandt

Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: s.brandt@ljmu.ac.uk

Contents

1) Representative photograph of a diphenidine product obtained online

2) ATR-IR and NMR data of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI

3) ATR-IR of 1-(1,2-diphenylethyl)piperidine (1,2-DEP, diphenidine) (1) and 1-(2,2-diphenylethyl)piperidine (2,2-DEP, diphenidine isomer) (2)

4) ATR-IR of 1-(1,2-diphenylethyl)pyrrolidine (1,2-DEPy) (3) and 1-(2,2-diphenylethyl)pyrrolidine (2,2-DEPy) (4)

5) ATR-IR of two diphenidine samples obtained online

6) GC-MS and EI ion trap MS spectra of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI

7) ESI-triple quadrupole tandem mass spectra of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI

8) LC-ESI-MS/MS chromatograms of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI

9) LC-ESI-MS/MS chromatograms 1-(1,2-diphenylethyl)pyrrolidine (1,2-DEPy) (3) and 1-(2,2-diphenylethyl)pyrrolidine (2,2-DEPy) (4)

10) GC-EI-MS traces of (1) - (4) and two diphenidine samples obtained online

11) LC-ESI-MS/MS traces of synthesized $(\mathbf{1})$ and $(\mathbf{2})$ and two diphenidine samples obtained online

12) ESI-triple quadrupole tandem mass spectra of two diphenidine samples obtained online

13) ¹H and ¹³C NMR of diphenidine free base and hydrochloride salt

14) Assigned ¹³C and ¹H aliphatic and chemical shifts in ppm for compounds (1) - (4) and (1) HCl

15) HPLC-DAD traces for synthesized diphenidine isomers (1) and (2) and comparison with a diphenidine sample obtained from an online test purchase

1) Representative photograph of a diphenidine product obtained online



Note: CAS number refers to the hydrochloride salt of diphenidine



Infrared (IR) spectra were obtained on a Perkin Elmer Spectrum BX FTIR model using a Pike MIRacle ATR system. Data were acquired with the Spectrum v5.01 software (scan range $4000_{-}400 \text{ cm}^{-1}$, resolution 4 cm⁻¹, 16 scans).



2) ATR-IR and NMR data of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI

NMR 1,2-diphenylethanamine base (m.p. HCl salt 252.5-254.0 °C):

¹H NMR (400 MHz, CDCl₃) δ 7.40-7.11 (10H, m, Ar-H), 4.19 (1H, dd, J = 8.8, 4.9 Hz, C₁H), 3.01 (1H, dd, J = 13.3, 4.9 Hz, C₂H), 2.83 (1H, dd, J = 13.3, 8.8 Hz, C₂H), 1.4 (2H, s, NH₂). ¹³C NMR (100 MHz, CDCl₃) δ 145.64 (quat. Ar-C), 139.09 (quat. Ar-C), 129.34 (Ar-CH), 128.39 (Ar-CH), 127.04 (Ar-CH), 126.42 (Ar-CH), 126.35 (Ar-CH), 57.55 (C₁H), 46.59 (CH₂).

NMR 2,2-diphenylethanamine base (m.p. HCl salt > 260 °C):

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.14 (10H, m, Ar-H), 3.98 (1H, t, *J* = 7.6 Hz, C₂H), 3.31 (2H, d, *J* = 7.6 Hz, C₁H₂), 1.45 (2H, s, NH₂). ¹³C NMR (100 MHz, CDCl₃) δ 142.69 (2 x quat. Ar-C), 128.61 (4 x Ar-CH), 128.08 (4 x Ar-CH), 126.52 (2 x Ar-CH), 55.02 (C₁H₂), 47.01 (C₂H).

3) ATR-IR of 1-(1,2-diphenylethyl)piperidine (1,2-DEP, diphenidine) (1) and 1-(2,2-diphenylethyl)piperidine (2,2-DEP, diphenidine isomer) (2)



4) ATR-IR of 1-(1,2-diphenylethyl)pyrrolidine (1,2-DEPy) (**3**) and 1-(2,2-diphenylethyl)pyrrolidine (2,2-DEPy) (**4**)





5) ATR-IR of two diphenidine samples obtained online

6) GC-MS and EI ion trap MS spectra of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI



7) ESI-triple quadrupole tandem mass spectra of 1,2-diphenylethanamine HCI & 2,2-diphenylethanamine HCI



165.89 100 [M+H]⁺at *m/z* 198 102.82 NH_2 180.92 181.12 % 164.74 71.91 178.93 140.91 ^{152.74} 71.41 83.77 0-4 ------- *m/z* 100 40 60 80 120 140 160 180 200 220 240

8) LC-ESI-MS/MS chromatograms of 1,2-diphenylethanamine HCI & 2,2diphenylethanamine HCI



Selected ion transitions:

m/z 198 > 72 (48 eV) *m/z* 198 > 103 (35 eV) *m/z* 198 > 166 (28 eV) *m/z* 198 > 181 (20 eV) 9) LC-ESI-MS/MS chromatograms 1-(1,2-diphenylethyl)pyrrolidine (1,2-DEPy) (3) and 1-(2,2-diphenylethyl)pyrrolidine (2,2-DEPy) (4)



Selected ion transitions:

m/z 252 > 72 (48 eV) m/z 252 > 103 (35 eV) m/z 252 > 166 (28 eV) m/z 252 > 181 (20 eV)

10) GC-EI-MS traces of (1) - (4) and two diphenidine samples obtained online



11) LC-ESI-MS/MS traces of synthesized (1) and (2) and two diphenidine samples obtained online



Selected ion transitions:

m/z 266 > 72 (48 eV) m/z 266 > 103 (35 eV) m/z 266 > 166 (28 eV) m/z 266 > 181 (20 eV) 12) ESI-triple quadrupole tandem mass spectra of two diphenidine samples obtained online



13) ¹H and ¹³C NMR of diphenidine free base



14) Assigned ¹³C and ¹H aliphatic and chemical shifts in ppm for compounds (1) - (4) and (1) HCl.

¹³ C	1,2-DEP HCI (1)	1,2-DEP (1)	2,2-DEP (2)	1,2-DEPy (3)	2,2-DEPy (4)		
Shift							
C ₁	72.90	72.32	64.53	73.31	61.74		
C ₂	36.75	39.18	48.89	42.96	50.87		
Cα	53.39	51.40	54.85	53.0	54.55		
	48.81						
C _β	22.71	26.37	25.99	23.35	23.50		
	22.65						
Cγ	22.24	24.66	24.43	-	-		
Assigned ¹³ C aliphatic chemical shifts in ppm for compounds $(1) - (4)$ and (1) HCl.							

¹ H Shift	1,2-DEP HCI (1)	1,2-DEP (1)	2,2-DEP (2)	1,2-DEPy (3)	2,2-DEPy (4)
C ₁	4.23 d	3.58, dd	2.93, d	3.30, dd	3.14, d
	(11.6, 1H)	(9.4, 5.2, 1H)	(7.3, 2H)	(9.9, 4.3, 1H)	(7.4, 2H)
C ₂	4.04 dd	3.30, dd	4.21, t	3.36, dd	4.22, t
	(12.8, 3.1, 1H)	(13.3, 5.2, 1H)	(7.3, 1H)	(13.3, 4.3, 1H)	(7.1, 1H)
	3.46 t	2.99, dd		2.96, dd	
	(12.2, 1H)	(13.4, 9.4, 1H)		(13.3, 9.9, 1H)	
Cα	3.64 d	2.55-2.29, m	2.39, t	2.64, m	2.51, t
	(10.3, 1H)	(4H)	(5.4, 4H)	(2H)	(6.1, 4H)
	3.54 d			2.45, m	
	(11.6, 1H)			(2H)	
	2.68-2.39 m (2H)				
C _β	2.68-2.39 m (1H)	1.64-1.45, m (4H)	1.46, quint (5.5, 4H)	1.77, quint (3.3, 4H)	1.72, quint (3.1, 4H)
	1.93-1.76 m (3H)		,	,	,
Cv	2.31 q	1.36, quint	1.37, quint	-	-
·	(13.2, 12.2, 1H)	(5.9, 2H)	(5.4, 2H)		
	1.27 q				
	(13.4, 12.4, 1H)				

Assigned ¹H aliphatic chemical shifts in ppm for compounds (1) - (4) and (1) HCl. m = multiplet; d = doublet; t = triplet; q = quartet; quint = quintet.

15) HPLC-DAD traces for synthesized diphenidine isomers (1) and (2) and comparison with a diphenidine sample obtained from an online test purchase. Note: The overlapping UV maxima for traces (a) and (c) were 257 and 267 nm, respectively.

Analytical details have been described in: Y.N. Soh, S. Elliott. An investigation of the stability of emerging new psychoactive substances. *Drug Test. Anal.* **2013**, in press; doi: 10.1002/dta.1576.

